| Expression pattern: |
UP |
| Associated gene: |
IGF2BP2, CD36, DDX39B |
| Associated microRNA: |
- |
| Biological function: |
CircZNF609 promotes bladder cancer immune escape, inhibits CD8+ T cell anti-tumour activity, suppresses anti-PD-1 immunotherapy sensitivity, promotes tumour growth, and enhances fatty acid uptake by BCa cells. |
| Molecular mechanism: |
CircZNF609 binds IGF2BP2 in the cytoplasm, enhances IGF2BP2 interaction with the CD36 3′UTR, increases CD36 mRNA stability in an m6A-dependent manner, promotes CD36-mediated fatty acid uptake, depletes fatty acids in the tumour microenvironment, and induces CD8+ T cell dysfunction; DDX39B regulates circZNF609 nuclear export. |
| Biological pathway or process: |
immune regulation (promotes); lipid metabolism (promotes); mRNA stability (promotes); m6A modification (other); drug resistance (promotes); proliferation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNA-seq; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; IF (Immunofluorescence); RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Actinomycin D / DRB Stability Assay; Transfection; ELISA; Flow Cytometry（Non-apoptosis/cycle）; Oil Red O Staining; Western Blot; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); Bioinformatics Analysis |
| Clinical significance: |
CircZNF609 holds potential as a biomarker and therapeutic target in bladder cancer immunotherapy and may predict susceptibility to immunotherapy. |
| Description: |
CircZNF609 is an oncogenic circRNA studied in bladder cancer that reduces sensitivity to anti-PD-1 immunotherapy and promotes immune escape. It acts through a circZNF609/IGF2BP2/CD36 mechanism, increasing CD36 mRNA stability and fatty acid uptake by cancer cells, thereby depleting fatty acids in the tumour microenvironment and impairing CD8+ T cell function. The study suggests circZNF609 may serve as a biomarker and therapeutic target for bladder cancer immunotherapy. |
| Confidence score: |
0.8108 |